Company: IMNN
Filing Date: 2025-03-19
Form Type: DRS
Source: 0001641172-25-000007
Chunk: 54

Company: Imunon, Inc.
Filing Date: 2025-03-19
Form: DRS
Chunk 54
---
 to Dr. Douglas Faller, our Chief Medical Officer, as an “inducement” grant pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. The grants of these awards were exempt from registration under the Securities Act, pursuant to Section 4(a)(2) thereof as a transaction by an issuer not involving a public offering..

Item 16. Exhibits and Financial Statement Schedules.

(a) The exhibits set forth below have been or are being filed herewith and are numbered in accordance with Item 601 of Regulation S-K.

| II-2 |

| CONFIDENTIAL TREATMENT REQUESTED BY IMUNON, INC.PURSUANT TO 17 C.F.R. SECTION 200.83 |

(b) Financial statement schedules have been omitted, as the information required to be set forth therein is included in the consolidated financial statements or notes thereto incorporated by reference into the prospectus forming part of this registration statement.

| EXHIBIT 
 NO.     |     | DESCRIPTION                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 1.1

#    |     | Form                                                                                                                                                                                                                                                                                                                                                                                                                                             
 of Placement Agency Agreement.                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 2.1*    |     | Asset Purchase Agreement dated as of June 6, 2014, by and between Imunon, Inc. and EGEN, Inc., incorporated herein by reference to Exhibit 2.1 to the Quarterly Report on Form 10-Q of the Company for the quarter ended June 30, 2014 (SEC File No. 001-15911).                                                                                                                                                                                 |
| 2.2     |     | Amendment to Asset Purchase Agreement between Celsion Corporation and EGWU, Inc., dated March 28, 2019 incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K of the Company filed on April 1, 2019 (SEC File No. 001-15911).                                                                                                                                                                                        |
| 3.1     |     | Amended and Restated Certificate of Incorporation of Imunon, dated March 24, 2023, incorporated herein by reference to Exhibit 3.1 to the Current Report on Form 8-K of the Company filed on March 24, 2023 (SEC File No. 001-15911).                                                                                                                                                                                                            |
| 3.2     |     | Amended and Restated Bylaws of the Company, effective on March 15, 2024, incorporated